Drug & intervention

dobutamine

RxCUI 3616

Clinical trials15
Recruiting0
Related conditions20
Synonyms14

Understanding this RxNorm record

RxNorm identifiers distinguish ingredients, specific strengths, dose forms, and branded products. They help connect equivalent terminology across data sources; an RxNorm entry does not by itself establish that a product is currently marketed, approved for a particular use, or appropriate for an individual.

Clinical-trial associations reflect registry-reported intervention names and verified mappings where available. A medication listed in a trial may be investigational for that condition. Consult the original study record and official prescribing information for indications and safety details.

Terminology source: National Library of Medicine RxNorm. Trial source: ClinicalTrials.gov.

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Dobutamine

Dobutamine is a medication used in the treatment of cardiogenic shock (as a result of inadequate tissue perfusion) and severe heart failure. It may also be used in certain types of cardiac stress tests. It is given by IV only, as an injection into a vein or intraosseous as a continuous infusion. The amount of medication needs to be adjusted to the desired effect. Onset of effects is generally seen within 2 minutes. It has a half-life of two minutes. This drug is generally only administered short term, although it may be used for longer periods to relieve symptoms of heart failure in patients awaiting heart transplantation. Common side effects include a fast heart rate, an irregular heart beat, and inflammation at the site of injection. Use is not recommended in those with idiopathic hypertrophic subaortic stenosis. It primarily works by direct stimulation of β1 receptors, which increases the strength of the heart's contractions, leading to a positive inotropic effect. Generally it has little effect on a person's heart rate. Dobutamine was approved for medical use in the United States in 1978. It is available as a generic medication. It was initially made from isoproterenol.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

15 shown
Dobutamine During Major Abdominal SurgeryNCT07000994 · 2025-06-16
COMPLETED
Clinical Outcomes of Levosimendan Versus Dobutamine Versus Milrinone in Cases With Acute Decompensated Heart Failure With Impaired Renal FunctionNCT07186062 · 2022-06-01
COMPLETED
Right Ventricular Contractile Reserve in HFNCT05797584 · 2019-03-20
UNKNOWN
Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart FailureNCT02767024 · 2018-05-01
WITHDRAWN
Haemodynamic Effects of Dobutamine and Nitrite in LV DysfunctionNCT02888561 · 2016-10-01
UNKNOWN
Dobutamaine Versus Milrinone in Cardiorenal SyndromeNCT02644057 · 2016-03-01
WITHDRAWN
Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 DiabetesNCT02505451 · 2015-07-01
COMPLETED
Levosimendan Versus Dobutamine for Renal Function in Heart FailureNCT02133105 · 2014-04-01
COMPLETED
Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure PatientsNCT01930734 · 2013-10-01
UNKNOWN
The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve ReplacementNCT01375335 · 2011-06-01
SUSPENDED
Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)NCT01354613 · 2011-04-01
COMPLETED
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)NCT00763035 · 2009-01-01
TERMINATED
Levosimendan Versus Dobutamine in Shock PatientsNCT00093301 · 2004-10-01
UNKNOWN
Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated CardiomyopathyNCT00281255 · 2003-06-01
WITHDRAWN
Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support: a Multicentre, Parallel-Group, Randomised, Double-Blind, Double-Dummy Study of Levosimendan Versus Dobutamine in Patients With Acute Heart Failure.NCT00348504 · 2003-03-01
COMPLETED

Conditions being studied

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.